Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
26
TCNNF Quote, Financials, Valuation and Earnings
Last price:
$6.22
Seasonality move
:
-6.02%
Day range:
$5.99 - $7.00
52-week range:
$3.02 - $11.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.07x
P/B ratio:
1.06x
Volume:
249.9K
Avg. volume:
231.3K
1-year change:
52.63%
Market cap:
$1.3B
Revenue:
$1.2B
EPS (TTM):
-$0.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TCNNF
Trulieve Cannabis Corp.
|
$297.5M | -$0.03 | -0.63% | -90.79% | $21.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.1M | $0.59 | 11.8% | 33.07% | $88.87 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
|
TLRY
Tilray Brands, Inc.
|
$211.1M | -- | 8.44% | -100% | $11.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TCNNF
Trulieve Cannabis Corp.
|
$6.67 | $21.00 | $1.3B | -- | $0.00 | 0% | 1.07x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.33 | $31.21 | $4.1B | 15.65x | $0.00 | 0% | 3.91x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$339.37 | $457.00 | $45B | 150.36x | $0.00 | 0% | 12.20x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$63.42 | $88.87 | $12.2B | 23.76x | $0.00 | 0% | 4.02x |
|
SVRA
Savara, Inc.
|
$5.72 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
|
TLRY
Tilray Brands, Inc.
|
$7.89 | $11.83 | $915.2M | -- | $0.00 | 0% | 0.95x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TCNNF
Trulieve Cannabis Corp.
|
40.31% | -0.660 | 53.38% | 3.72x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
|
TLRY
Tilray Brands, Inc.
|
16.83% | 3.038 | 35.13% | 1.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TCNNF
Trulieve Cannabis Corp.
|
$140.4M | $45.2M | -6.43% | -10.71% | 15.69% | $60.8M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
|
TLRY
Tilray Brands, Inc.
|
$53.1M | -$20M | -84.8% | -98.18% | -9.2% | -$18M |
Trulieve Cannabis Corp. vs. Competitors
-
Which has Higher Returns TCNNF or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -8.24% compared to Trulieve Cannabis Corp.'s net margin of 25.76%. Trulieve Cannabis Corp.'s return on equity of -10.71% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital TCNNFTrulieve Cannabis Corp.48.72% -$0.14 $2B ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About TCNNF or ACAD?
Trulieve Cannabis Corp. has a consensus price target of $21.00, signalling upside risk potential of 214.84%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 28.28%. Given that Trulieve Cannabis Corp. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Trulieve Cannabis Corp. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCNNFTrulieve Cannabis Corp.7 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is TCNNF or ACAD More Risky?
Trulieve Cannabis Corp. has a beta of 1.135, which suggesting that the stock is 13.508% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock TCNNF or ACAD?
Trulieve Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis Corp. pays 0.7% of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Trulieve Cannabis Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TCNNF or ACAD?
Trulieve Cannabis Corp. quarterly revenues are $288.2M, which are larger than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Trulieve Cannabis Corp.'s net income of -$23.7M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Trulieve Cannabis Corp.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis Corp. is 1.07x versus 3.91x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCNNFTrulieve Cannabis Corp.1.07x -- $288.2M -$23.7M ACADACADIA Pharmaceuticals, Inc.3.91x 15.65x $278.6M $71.8M
-
Which has Higher Returns TCNNF or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -8.24% compared to Trulieve Cannabis Corp.'s net margin of 16.99%. Trulieve Cannabis Corp.'s return on equity of -10.71% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital TCNNFTrulieve Cannabis Corp.48.72% -$0.14 $2B ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About TCNNF or ALNY?
Trulieve Cannabis Corp. has a consensus price target of $21.00, signalling upside risk potential of 214.84%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 34.66%. Given that Trulieve Cannabis Corp. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Trulieve Cannabis Corp. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCNNFTrulieve Cannabis Corp.7 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is TCNNF or ALNY More Risky?
Trulieve Cannabis Corp. has a beta of 1.135, which suggesting that the stock is 13.508% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock TCNNF or ALNY?
Trulieve Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis Corp. pays 0.7% of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Trulieve Cannabis Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TCNNF or ALNY?
Trulieve Cannabis Corp. quarterly revenues are $288.2M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Trulieve Cannabis Corp.'s net income of -$23.7M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Trulieve Cannabis Corp.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 150.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis Corp. is 1.07x versus 12.20x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCNNFTrulieve Cannabis Corp.1.07x -- $288.2M -$23.7M ALNYAlnylam Pharmaceuticals, Inc.12.20x 150.36x $1.1B $186.4M
-
Which has Higher Returns TCNNF or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -8.24% compared to Trulieve Cannabis Corp.'s net margin of -3.91%. Trulieve Cannabis Corp.'s return on equity of -10.71% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital TCNNFTrulieve Cannabis Corp.48.72% -$0.14 $2B BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About TCNNF or BMRN?
Trulieve Cannabis Corp. has a consensus price target of $21.00, signalling upside risk potential of 214.84%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 40.13%. Given that Trulieve Cannabis Corp. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Trulieve Cannabis Corp. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCNNFTrulieve Cannabis Corp.7 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is TCNNF or BMRN More Risky?
Trulieve Cannabis Corp. has a beta of 1.135, which suggesting that the stock is 13.508% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock TCNNF or BMRN?
Trulieve Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis Corp. pays 0.7% of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend. Trulieve Cannabis Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TCNNF or BMRN?
Trulieve Cannabis Corp. quarterly revenues are $288.2M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Trulieve Cannabis Corp.'s net income of -$23.7M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Trulieve Cannabis Corp.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 23.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis Corp. is 1.07x versus 4.02x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCNNFTrulieve Cannabis Corp.1.07x -- $288.2M -$23.7M BMRNBioMarin Pharmaceutical, Inc.4.02x 23.76x $786.8M -$30.7M
-
Which has Higher Returns TCNNF or SVRA?
Savara, Inc. has a net margin of -8.24% compared to Trulieve Cannabis Corp.'s net margin of --. Trulieve Cannabis Corp.'s return on equity of -10.71% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital TCNNFTrulieve Cannabis Corp.48.72% -$0.14 $2B SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About TCNNF or SVRA?
Trulieve Cannabis Corp. has a consensus price target of $21.00, signalling upside risk potential of 214.84%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 89.03%. Given that Trulieve Cannabis Corp. has higher upside potential than Savara, Inc., analysts believe Trulieve Cannabis Corp. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCNNFTrulieve Cannabis Corp.7 0 0 SVRASavara, Inc.6 0 0 -
Is TCNNF or SVRA More Risky?
Trulieve Cannabis Corp. has a beta of 1.135, which suggesting that the stock is 13.508% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock TCNNF or SVRA?
Trulieve Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis Corp. pays 0.7% of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend. Trulieve Cannabis Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TCNNF or SVRA?
Trulieve Cannabis Corp. quarterly revenues are $288.2M, which are larger than Savara, Inc. quarterly revenues of --. Trulieve Cannabis Corp.'s net income of -$23.7M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Trulieve Cannabis Corp.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis Corp. is 1.07x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCNNFTrulieve Cannabis Corp.1.07x -- $288.2M -$23.7M SVRASavara, Inc.-- -- -- -$29.6M
-
Which has Higher Returns TCNNF or TLRY?
Tilray Brands, Inc. has a net margin of -8.24% compared to Trulieve Cannabis Corp.'s net margin of -20%. Trulieve Cannabis Corp.'s return on equity of -10.71% beat Tilray Brands, Inc.'s return on equity of -98.18%.
Company Gross Margin Earnings Per Share Invested Capital TCNNFTrulieve Cannabis Corp.48.72% -$0.14 $2B TLRYTilray Brands, Inc.24.43% -$0.41 $1.9B -
What do Analysts Say About TCNNF or TLRY?
Trulieve Cannabis Corp. has a consensus price target of $21.00, signalling upside risk potential of 214.84%. On the other hand Tilray Brands, Inc. has an analysts' consensus of $11.83 which suggests that it could grow by 49.87%. Given that Trulieve Cannabis Corp. has higher upside potential than Tilray Brands, Inc., analysts believe Trulieve Cannabis Corp. is more attractive than Tilray Brands, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCNNFTrulieve Cannabis Corp.7 0 0 TLRYTilray Brands, Inc.2 7 0 -
Is TCNNF or TLRY More Risky?
Trulieve Cannabis Corp. has a beta of 1.135, which suggesting that the stock is 13.508% more volatile than S&P 500. In comparison Tilray Brands, Inc. has a beta of 2.022, suggesting its more volatile than the S&P 500 by 102.181%.
-
Which is a Better Dividend Stock TCNNF or TLRY?
Trulieve Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis Corp. pays 0.7% of its earnings as a dividend. Tilray Brands, Inc. pays out -- of its earnings as a dividend. Trulieve Cannabis Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TCNNF or TLRY?
Trulieve Cannabis Corp. quarterly revenues are $288.2M, which are larger than Tilray Brands, Inc. quarterly revenues of $217.5M. Trulieve Cannabis Corp.'s net income of -$23.7M is higher than Tilray Brands, Inc.'s net income of -$43.5M. Notably, Trulieve Cannabis Corp.'s price-to-earnings ratio is -- while Tilray Brands, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis Corp. is 1.07x versus 0.95x for Tilray Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCNNFTrulieve Cannabis Corp.1.07x -- $288.2M -$23.7M TLRYTilray Brands, Inc.0.95x -- $217.5M -$43.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
